Released Feb 27, 2025, before the open
10-K filed Feb 27, 2025, 58 days after period end · 0001171843-25-001106
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$15.03M-$15.03M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$16,571,000N/M
Operating Cash Flowderived-$9,162,000N/M
Free Cash Flowderived-$9,162,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$15.03M | -$13.42M | -$11.59M | -$12.98M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR